Leerink Partnrs Has Pessimistic View of Geron Q2 Earnings

Geron Co. (NASDAQ:GERN) – Equities research analysts at Leerink Partnrs cut their Q2 2025 earnings per share (EPS) estimates for Geron in a note issued to investors on Monday, January 6th. Leerink Partnrs analyst F. Khurshid now anticipates that the biopharmaceutical company will earn $0.00 per share for the quarter, down from their previous estimate of $0.01. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. Leerink Partnrs also issued estimates for Geron’s Q3 2025 earnings at $0.01 EPS and Q4 2025 earnings at $0.02 EPS.

Geron (NASDAQ:GERN) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.05. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The company had revenue of $28.27 million for the quarter, compared to analyst estimates of $18.97 million. During the same period in the previous year, the firm earned ($0.08) earnings per share. Geron’s revenue for the quarter was up 17138.4% compared to the same quarter last year.

Several other research analysts also recently weighed in on GERN. Needham & Company LLC reissued a “buy” rating and issued a $6.00 target price on shares of Geron in a research report on Friday, December 13th. HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of Geron in a research report on Tuesday, December 10th. Scotiabank assumed coverage on Geron in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $6.00 target price for the company. Finally, Barclays upgraded Geron to a “strong-buy” rating in a report on Friday, November 29th. One analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $7.15.

Geron Price Performance

NASDAQ GERN opened at $3.40 on Tuesday. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04. Geron has a 1 year low of $1.64 and a 1 year high of $5.34. The company has a market cap of $2.06 billion, a PE ratio of -10.63 and a beta of 0.55. The stock’s 50-day moving average price is $3.85 and its two-hundred day moving average price is $4.25.

Institutional Trading of Geron

Several hedge funds and other institutional investors have recently modified their holdings of the company. National Bank of Canada FI increased its position in Geron by 1,200.0% in the 2nd quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 6,000 shares during the last quarter. Readystate Asset Management LP acquired a new stake in shares of Geron during the 3rd quarter valued at about $58,000. Rovin Capital UT ADV bought a new stake in shares of Geron in the 3rd quarter valued at approximately $62,000. Empowered Funds LLC acquired a new position in Geron in the third quarter worth approximately $67,000. Finally, Inspire Advisors LLC bought a new position in Geron during the third quarter valued at approximately $68,000. 73.71% of the stock is currently owned by hedge funds and other institutional investors.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.